IL1B and Opportunistic infection: However, several disadvantages of these biologics cannot be ignored: (i) NLRP3 inflammasome activation produces not only IL‐1β but also IL‐18, which may be involved in pathogenic and immunomodulatory process [27]; (ii) most biologics cannot be administered orally and have limited ability to penetrate the blood‒brain barrier; (iii) IL‐1β produced by other inflammasomes may have normal physiological functions, and blockage of IL‐1β increases the risk of opportunistic infections [28].